The International Collaboration on Cosmetics Safety enters a new chapter with the appointment of its 2026 Board officers, reinforcing its global commitment to advancing animal-free approaches in cosmetics safety science at a time of rapid regulatory and scientific change.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its 2026 Board officers after elections held during the organization’s December 2025 Board meeting, a milestone that underscores how this relatively young global initiative is solidifying its position in promoting scientifically robust, human‑relevant alternatives to animal testing in cosmetics safety assessment. The newly selected leadership reflects continuity as well as the organization’s growing sophistication, building on a year of significant accomplishments while positioning itself to expand its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the intersection of science, policy, and collaboration, bringing together diverse stakeholders who share a common objective: accelerating the global adoption and acceptance of animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers underscores the organization’s intention to maintain strategic focus while navigating an increasingly complex international landscape, where expectations for ethical research, scientific rigor, and regulatory alignment continue to evolve.
Leadership continuity and global representation
The 2026 Board leadership unites senior leaders from the cosmetics, consumer goods, and regulatory advocacy fields, capturing the multi-stakeholder character that has shaped ICCS from the start. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been chosen again to serve as Chair of the Board of Directors. His renewed appointment reflects sustained trust in a leadership style grounded in scientific rigor, international collaboration, and productive dialogue with regulatory authorities.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose experience in industry representation and regulatory dialogue adds a valuable regional and policy-oriented perspective. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing deep expertise in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing extensive experience in toxicology leadership and governance.
Together, the officers constitute a leadership team whose background extends across multinational corporations, industry groups, and regulatory science, thereby strengthening ICCS’ role as a neutral forum for collaboration rather than a promoter of any individual sector. This equilibrium remains essential to the organization’s credibility, especially as it aims to shape regulatory perspectives and foster alignment on animal-free safety approaches.
Driving progress in animal-free science through collective collaboration
At the core of ICCS’ mission lies the conviction that animal-free safety assessment methods, when rigorously designed and validated, are not only ethically favorable but also scientifically stronger. Since its establishment in early 2023, ICCS has sought to show that non-animal approaches can deliver dependable, relevant insights to safeguard both human well-being and the environment. The confirmation of the 2026 Board officers arrives at a time when this message is gaining momentum, bolstered by concrete achievements and increasing involvement from regulators worldwide.
Throughout 2025, ICCS rolled out multiple initiatives that strengthened its scientific foundation while extending its overall impact. Among these, it released a Best Practice Guidance document designed to bring greater clarity and consistency to the application of animal‑free safety assessment approaches. This resource aimed to bridge the divide between scientific advances and regulatory expectations, offering a practical tool that stakeholders could rely on when producing or evaluating non‑animal data.
In parallel, ICCS also played a key role in shaping innovative methodologies that align with next generation risk assessment (NGRA), an evolving framework that integrates advanced in vitro, in silico, and exposure-led approaches. These techniques are increasingly viewed as essential to modern toxicology, offering more human-relevant insights while reducing reliance on animal testing. ICCS’ efforts in this field highlight its commitment to ethical advancement and scientific excellence.
Equally important has been the organization’s emphasis on dialogue. Throughout 2025, ICCS engaged extensively with regulators, scientists, and policymakers across multiple regions, contributing to discussions on how animal-free data can be interpreted and accepted within existing regulatory frameworks. These conversations have been instrumental in building shared understanding and trust, particularly in jurisdictions where regulatory acceptance of non-animal methods is still developing.
A pivotal milestone reshaping the oversight of cosmetics safety
The appointment of the 2026 Board officers takes place against a backdrop of significant change in global cosmetics regulation. Many markets are reassessing long-standing testing requirements, responding to public expectations, scientific advances, and international policy trends. In this context, organizations like ICCS play a critical role in helping align innovation with regulation, ensuring that progress is both credible and sustainable.
ICCS leadership has consistently emphasized that the transition to animal-free safety science cannot be achieved through isolated efforts. Instead, it requires coordinated action across industry, academia, regulators, and civil society. The composition of the Board reflects this philosophy, bringing together leaders who understand the technical, regulatory, and organizational dimensions of change.
ICCS leadership statements after the elections conveyed a blend of confidence and pragmatism. They noted the progress achieved in recent years while recognizing that substantial challenges persist. Securing broad regulatory endorsement for animal-free methodologies will demand sustained research investment, open data dissemination, and continuous collaboration with authorities to respond to valid concerns about reliability, real-world relevance, and safeguarding public health.
The re-elected Chair emphasized the importance of leveraging ICCS’ global, multi-stakeholder model to close the gap between innovation and regulation. This approach aims to ensure that advances in animal-free science are not confined to research settings but translated into practical tools that regulators can trust and apply consistently.
Strengthening foundations for long-term impact
As ICCS looks toward 2026 and the years to follow, the organization stays dedicated to expanding its impact while reinforcing its achievements. The newly appointed Board leadership is anticipated to play a central role in shaping priorities that blend scientific ambition with practical implementation. This includes identifying fields that need additional direction or agreement, advancing the validation and spread of new methodologies, and promoting global harmonization to reduce inconsistencies in regulatory expectations.
Education remains a core element of ICCS’ strategy, as the organization works to provide accessible, science‑based resources and forums for discussion that illuminate the foundations of animal‑free safety science and enable well‑informed decision‑making. This mission becomes particularly crucial in a field where misconceptions or uneven expertise may slow progress, even when the underlying science is strong.
The organization’s structure, encompassing leading cosmetics and ingredient producers alongside trade and research groups as well as animal protection organizations, places it in a distinctive position to tackle these challenges. This broad range of viewpoints helps keep discussions balanced, well‑rooted, and oriented toward common objectives rather than limited agendas.
Based in New York, ICCS continues to operate as a global initiative, highlighting the international scope of cosmetic innovation and regulatory supervision. As products and their components move across borders, harmonized guidelines and mutual recognition of safety protocols become increasingly vital. Through collaborative efforts, ICCS seeks to encourage this coherence, reduce duplicated work, and reinforce trust in animal-free science worldwide.
By confirming its 2026 Board officers, ICCS underscores both consistency and a clear drive toward progress, with a leadership group that extends the momentum of a year defined by tangible accomplishments while offering the insight and expertise required to steer the coming stage of transformation; as scientific innovation quickens and regulatory expectations shift, the organization’s function as a unifying force and driver of animal-free cosmetics safety science is poised to gain even greater significance.
Ultimately, the importance of the 2026 Board elections rests not only on who is selected, but also on what their leadership conveys: a continued dedication to cooperation, scientific rigor, and the ethical progress of alternatives to animal testing. For ICCS and its stakeholders, the years ahead present a chance to turn ambition into enduring results, guiding the evolution of cosmetics safety in a manner that brings ethics, scientific excellence, and global public confidence into alignment.
